Social News
Written by: Zhu Haiqi
2021-04-08 11:16
The last update date: 2021-04-08 11:17
The vaccine jointly developed by Oxford University and AstraZeneca, which Hong Kong intends to purchase, has been established by the European Medicines Agency to be related to cases of cerebral thrombosis.
Government expert Xu Shuchang and President of the Institute of Pharmacists Cui Junming respectively suggested that the government abandon or reduce the purchase of the AstraZeneca vaccine and switch to the one-dose US Johnson & Johnson vaccine. They also pointed out that the vaccine’s protection rate against the South African variant virus was as high as 50%.
Cui Junming suspected that the vaccine activated antibodies to embolize platelets
The European Medicines Agency recently stated that the vaccinators have blood clots in the brain, which are very rare side effects of the AstraZeneca vaccine.
Cui Junming, president of the Hong Kong Institute of Hospital Pharmacists, stated on the Radio Television Hong Kong program "Millenniums" that the authorities assessed that cerebral venous sinus thrombosis is associated with low platelet levels in vaccinated patients. It is suspected that it is related to vaccine-activated antibodies that cause platelet embolism and platelet Xiaoping also decreases.
He pointed out that before the new crown vaccine, there were 2 to 3 people with cerebral venous sinus thrombosis per 1 million people in Europe each year, but the current German data has risen to 10 cases per 1 million people, which is significantly higher because the European Medicines Agency believes To add warnings to the instructions.
The concentration of cerebral venous sinus thrombosis in young women is probably related to the local women taking more contraceptives
He mentioned that the cases of cerebral venous sinus thrombosis among vaccinators are concentrated in young European women. It is estimated that local women take contraceptives because the drug itself may cause blood clots.
Cui Junming pointed out that the Hong Kong government has signed an agreement with AstraZeneca earlier that it may be necessary to purchase a certain amount of vaccines. It is recommended that the government significantly reduce the number from 7.5 million doses to halve to avoid waste. "Hong Kong citizens (negative reports) are sensitive to You may not want to be vaccinated with any side effects.” I believe that the government should not only rely on the existing Kexing and Fubitai vaccines. For example, the previous Fubitai vaccine had packaging problems and could only rely on the Kexing vaccine, which is risky to the Hong Kong vaccination plan. .
Advocate the government to purchase Johnson & Johnson vaccines
Cui Junming suggested that the government purchase a US Johnson & Johnson vaccine that only requires one dose, because the vaccine has a high effect on the clinical data of the South African variant virus. On the contrary, Fubitai only has laboratory data and no actual clinical figures.
Like AstraZeneca, Johnson & Johnson vaccine uses adenovirus vector technology. Cui Junming said that the adenovirus of Johnson & Johnson vaccine is derived from humans, and AstraZeneca is from African chimpanzees. There may be a difference between them. It has not been heard that Johnson & Johnson vaccine increases cerebral venous sinus thrombosis. risk.
Xu Shuchang, a government expert consultant and chair professor of the Department of Respiratory System at CUHK, said on the same program that there is no dispute that the case of cerebral venous sinus thrombosis is related to the AstraZeneca vaccine. Even rare side effects can be prohibitive. Only 10% of the protection rate is by no means the best choice. I do not recommend the government to buy it. I think the government can also consider the Johnson & Johnson vaccine. The advantage is that only one dose is needed, and the protection rate against the South African variant virus is at least 50%.
The World Health Organization has approved the use of Johnson & Johnson vaccine, which has also been introduced in 37 countries, including the United States, Canada, Germany, Spain and Thailand.
AstraZeneca Vaccines | Many countries have updated their vaccination guidelines to increase the age of vaccination
AstraZeneca intends to modify product information WHO: Vaccines and thrombosis or causal relationship
AstraZeneca Vaccines | The UK recommends other vaccinations for people under 30
01News
New crown pneumonia AstraZeneca vaccine